Tampilkan postingan dengan label ACTH. Tampilkan semua postingan
Tampilkan postingan dengan label ACTH. Tampilkan semua postingan

Senin, 30 Januari 2017

More pharma price gouging


Today’s Managing Health Care Costs Number is $1.15 billion




Mallinckrodt Pharmaceuticals is in the news again; Gretchen Morgenson of the New York Times has noted that the company did not disclose FTC queries about anticompetitive behavior in 2014 -- when the company was considering acquiring Questcor.  Mallinckrodt just paid a $100 million fine for anticompetitive behavior.

HP Acthar Gel, the only product of Questcor when it was purchased by Mallinckrodt, is now responsible for more than a billion in annual sales.   The right to manufacture this generic non-patent-protected drug was purchased by Questcor for just $100,000 in 2001, when a vial went for $40.   Questcor paid Novartis $135 million in 2013 to purchase the rights to a synthetic version of the drug which is sold at a low price in Europe and Canada.  Questcor turned around and just put it on a shelf – and now a single vial of HP Acthar Gel costs $38,000!

Mallinckrodt just paid the recent fine to the FTC for its anticompetitive behavior around the Questcor purchase of the rights to the synthetic competitor (without admitting guilt).    A hundred million is a small price to pay for a drug where Medicare pays $162,000 a year per user!



 Screenshot from CMS dashboard